A5029292543- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Obsessive-Compulsive Spectrum Disorders
- Botulinum Toxin and Related Neurological Disorders
- Eating Disorders and Behaviors
- Epilepsy research and treatment
- Schizophrenia research and treatment
- Autism Spectrum Disorder Research
- Dysphagia Assessment and Management
- Ion channel regulation and function
- Genetic Neurodegenerative Diseases
- Motor Control and Adaptation
- Glycogen Storage Diseases and Myoclonus
- Temporomandibular Joint Disorders
- Cerebral Palsy and Movement Disorders
- Trigeminal Neuralgia and Treatments
- Nuclear Receptors and Signaling
- Advanced Mathematical Modeling in Engineering
- Muscle activation and electromyography studies
- Restless Legs Syndrome Research
- Pharmacological Effects and Toxicity Studies
- Uterine Myomas and Treatments
- EEG and Brain-Computer Interfaces
Université de Montréal
2012-2024
Institut Universitaire en Santé Mentale de Québec
2015-2024
Hôpital Louis-H Lafontaine
2011-2024
Centre Hospitalier de l’Université de Montréal
1999-2020
Douglas Mental Health University Institute
2016-2020
Ontario Neurotrauma Foundation
2016
University of Dental Medicine
2015
Université Laval
1988-2011
Hôpital Notre-Dame
1977-2008
Hôtel-Dieu de Montréal
2003-2005
Prevalence, symptoms, and treatment of depression suggest that major depressive disorders (MDD) present sex differences. Social stress-induced neurovascular pathology is associated with symptoms in male mice; however, this association unclear females. Here, we report chronic social subchronic variable stress promotes blood-brain barrier (BBB) alterations mood-related brain regions female mice. Targeted disruption the BBB prefrontal cortex (PFC) induces anxiety- depression-like behaviours. By...
Mesencephalic dopaminergic (MesDA) neurons play crucial roles in motor and behavioral processes; their loss Parkinson's disease (PD) results striatal dopamine (DA) deficiency hypokinetic movement disorder. The Pitx3 homeobox gene is expressed the MesDA system. We now show that only a subset of express Pitx3-deficient aphakia mice, this progressively lost by apoptosis during fetal (substantia nigra, SN) postnatal (ventral tegmental area) development, resulting very low DA akinesia. Similar to...
<b><i>Objective:</i></b> To evaluate the contribution of amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) glutamate receptors to pathogenesis parkinsonian signs and levodopa-induced dyskinesias. <b><i>Background:</i></b> Motor fluctuations dyskinesias reflect, in part, altered function NMDA subtype. The possible role AMPA receptors, however, has not yet been examined. <b><i>Methods:</i></b> authors compared ability an agonist (CX516) a noncompetitive antagonist (LY300164) alter...
Abstract Using an antibody that recognizes the products of all known members fos family immediate early genes, it was demonstrated destruction nigrostriatal pathway by 6‐hydroxydopamine (6‐OHDA) lesions medial forebrain bundle produces a prolonged (>3 months) elevation Fos‐like immunoreactivity in striatum. retrograde tract tracing techniques, we have previously shown this increase Foslike is located predominantly striatal neurons project to globus pallidus. In present study, Western...
Abstract The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa‐primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3–6 days). When with a relatively low dose levodopa, produced near‐total suppression choreiform dyskinesias and substantial reduction dystonic at expense significant antiparkinsonian response. With high had smaller but still effect on without...
The antiparkinsonian and antidyskinetic profile of two N-methyl-D-aspartate (NMDA) receptor antagonists, a competitive antagonist, (R)-4-oxo-5-phosphononorvaline (MDL 100,453), novel noncompetitive allosteric site 4-hydroxy-N-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piper idi ne (Co 101244/PD 174494), was assessed in six levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine-lesioned parkinsonian monkeys. effects on motor function these drugs, alone combination with levodopa, were then...
We compared the behavioral effects of a novel and highly selective dopamine D2 receptor agonist, U-91356A, administered to 6 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed parkinsonian monkeys for 27 days following an intermittent (n = 3) or continuous schedule, using subcutaneous osmotic minipumps latter group. Each group received equivalent amount drug daily. Dopamine D1 binding assays were performed on striatal tissue homogenates with tritiated antagonists those 3 healthy...
Objective : To characterize postural stability control and levodopa responsiveness in early Parkinson's disease (PD). Methods Postural sway was studied during quiet stance ten patients within six years of PD onset, both before (OFF) after (ON) regular oral dosing. recorded using a force platform 30 sec with eyes open, dependent variables were examined. Results Mild baseline subclinical changes our patients. Clear benefit observed five out characteristics (mean sway, transversal sagittal...
<b><i>Objective:</i></b> To examine the effect of 17β-estradiol on severity cardinal signs PD in postmenopausal women. <b><i>Background:</i></b> Although impact estrogens manifestations has not been subjected to rigorous study, their use is generally thought be associated with a detrimental antidopaminergic effect. <b><i>Methods:</i></b> A double-blind, placebo-controlled, two-arm crossover study high-dose transdermal was conducted eight women mild moderate PD, all but one whom exhibited...
The motor effects of selective D-1 dopamine receptor stimulation in Parkinson's disease have been explored a limited number studies with partial agonists only and the results were unsatisfactory. Four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed parkinsonian monkeys already exhibiting levodopa- agonist-induced dyskinesia received ([2,3,4,5-tetrahydro-7-8-dihydroxy-1-phenyl-1-H-3-benzazepine- HCI] (SKF 38393), [(+-)6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-...
Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication arising in patients chronically exposed to centrally active dopamine D2 receptor antagonists, including antipsychotic drugs metoclopramide. The classical supersensitivity hypothesis TD, which stemmed from rodent studies, lacks strong support humans. To investigate the neurochemical basis of we adult capuchin monkeys haloperidol (median, 18.5 months; n = 11) or clozapine 6 6). Six unmedicated animals were...
As part of a larger study, polysomnographic and audiovisual data were recorded over 2 nights in 41 subjects with clinical diagnosis sleep bruxism (SB). Electromyographic (EMG) events related to SB scored according standard criteria (Lavigne et al. J Dent Res 1996;75:546-552). Post hoc analysis revealed that rapid shock-like contractions the characteristics myoclonus jaw muscles observed four subjects. EMG bursts characterized as significantly shorter duration than classified SB. None had any...
This study was designed to assess the effects of bromocriptine, a dopamine D2 receptor agonist, on sleep bruxism. Seven otherwise healthy patients with severe and frequent bruxism participated in this randomized, double-blind, placebo-controlled study. The used crossover design that included 2 weeks active treatment or placebo washout period 1 week. To further evaluate whether bromocriptine influences striatal binding, we iodine-123-iodobenzamide single photon emission computed tomography...